Předmět: |
|
Zdroj: |
Clinical Oncology Week; 10/22/2024, p270-270, 1p |
Abstrakt: |
A recent study from the Chinese Academy of Sciences explores the role of the HIF-1a-HPRT1 axis in promoting tumorigenesis and gefitinib resistance in EGFR-mutant lung adenocarcinoma. The research reveals that mutated EGFR upregulates HPRT1 to enhance purine metabolism, leading to rapid tumor cell proliferation. The study suggests that inhibiting purine metabolism could be a potential strategy for treating EGFR-mutant lung adenocarcinoma. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|